Literature DB >> 1711635

Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats.

N Fujita1, M Hiroe, Y Ohta, T Horie, S Hosoda.   

Abstract

This study was designed to clarify whether chronic administration of metoprolol had any influence on cardiac beta-adrenergic receptors (BAR) in doxorubicin (DOX)-induced cardiac damage. DOX was injected through the tail vein into rats (3 mg/kg/week, n = 22) for 5 weeks. One week after the final injection, the rats were randomly divided into two groups, M (with metoprolol, 10 mg/kg/day subcutaneously, s.c.; n = 11) and D (without metoprolol; n = 11). After 3-week infusion, plasma norepinephrine (NE) levels and BAR density [[125I]iodocyanopindolol (ICYP) binding on crude membranes] were measured. Left and right ventricular end-diastolic pressure (LVEDP, RVEDP) and myocardial NE levels were also measured, and the results were compared with those from an age-matched control group (C n = 11). Decreased BAR density and increased plasma NE levels were evident in group D, indicating downregulation. In group M, BAR density and plasma NE levels were similar to those in group C. The myocardial NE levels were decreased in group D, but were higher in group M than in group D. The LVEDP and RVEDP were increased in group D, but were almost normal in group M. These results suggest that metoprolol is a promising drug for treatment of DOX-induced cardiac damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711635     DOI: 10.1097/00005344-199104000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Omega-3 polyunsaturated fatty acids prevent murine dilated cardiomyopathy by reducing oxidative stress and cardiomyocyte apoptosis.

Authors:  Qianxiao Li; Qin Yu; Rongmei Na; Baiting Liu
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

2.  Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy.

Authors:  Giovanni Fajardo; Mingming Zhao; Jennifer Powers; Daniel Bernstein
Journal:  J Mol Cell Cardiol       Date:  2006-02-03       Impact factor: 5.000

3.  Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling.

Authors:  Liangliang Zhou; Lanping Chen; Jing Wang; Yijun Deng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 4.  Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure.

Authors:  D Baran; E M Horn; K Hryniewicz; S D Katz
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

Review 5.  Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.

Authors:  Neha Bansal; M Jacob Adams; Sarju Ganatra; Steven D Colan; Sanjeev Aggarwal; Rudolf Steiner; Shahnawaz Amdani; Emma R Lipshultz; Steven E Lipshultz
Journal:  Cardiooncology       Date:  2019-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.